Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

814 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Kaasch AJ, López-Cortés LE, Rodríguez-Baño J, Cisneros JM, Dolores Navarro M, Fätkenheuer G, Jung N, Rieg S, Lepeule R, Coutte L, Bernard L, Lemaignen A, Kösters K, MacKenzie CR, Soriano A, Hagel S, Fantin B, Lafaurie M, Talarmin JP, Dinh A, Guimard T, Boutoille D, Welte T, Reuter S, Kluytmans J, Martin ML, Forestier E, Stocker H, Vitrat V, Tattevin P, Rommerskirchen A, Noret M, Adams A, Kern WV, Hellmich M, Seifert H; SABATO study group. Kaasch AJ, et al. Among authors: reuter s. Lancet Infect Dis. 2024 May;24(5):523-534. doi: 10.1016/S1473-3099(23)00756-9. Epub 2024 Jan 17. Lancet Infect Dis. 2024. PMID: 38244557 Clinical Trial.
Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial.
Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, Paulus U, Hellmich M, Weiß V, Jung N, Rieg S, Kern WV, Seifert H; SABATO trial group (with linked authorship to the individuals in the Acknowledgements section). Kaasch AJ, et al. Trials. 2015 Oct 9;16:450. doi: 10.1186/s13063-015-0973-x. Trials. 2015. PMID: 26452342 Free PMC article. Clinical Trial.
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Wilcox MH, et al. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615. N Engl J Med. 2017. PMID: 28121498 Free article. Clinical Trial.
Comprehensive vs. standard remote monitoring of cardiac resynchronization devices in heart failure patients: results of the ECOST-CRT study.
Klein C, Kouakam C, Lazarus A, de Groote P, Bauters C, Marijon E, Mouquet F, Degand B, Guyomar Y, Mansourati J, Leclercq C, Guédon-Moreau L; ECOST-CRT study Investigators. Klein C, et al. Europace. 2024 Oct 3;26(10):euae233. doi: 10.1093/europace/euae233. Europace. 2024. PMID: 39400005 Free PMC article. Clinical Trial.
Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity.
Herrmann A, Gege C, Wangen C, Wagner S, Kögler M, Cordsmeier A, Irrgang P, Ip WH, Weil T, Hunszinger V, Groß R, Heinen N, Pfaender S, Reuter S, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Grunwald T, Hietel B, Cynis H, Münch J, Sparrer KMJ, Ensser A, Tenbusch M, Dobner T, Vitt D, Kohlhof H, Hahn F. Herrmann A, et al. Among authors: reuter s. Antiviral Res. 2024 Sep 19;231:106008. doi: 10.1016/j.antiviral.2024.106008. Online ahead of print. Antiviral Res. 2024. PMID: 39306285 Free article.
814 results